Background: Somatostatin analogues have been used with conflicting results to treat advanced hepatocellular carcinoma (HCC). The aim of this study was to investigate expression of somatostatin receptor (SSTR) subtypes in human liver, and to examine the effect of selective SSTR agonists on proliferation, apoptosis, and migration of hepatoma cells (HepG2, HuH7) and hepatic stellate cells (HSCs). Methods: Expression of SSTRs in cell lines, normal and cirrhotic liver, and HCC was examined by immunohistochemistry and reverse transcription-polymerase chain reaction. Effects of SSTR agonists on proliferation and apoptosis of tumour cells and HSCs were assessed by the 5-bromo-29 deoxyuridine and TUNEL methods, respectively. The influence of SSTR agonists on migration was investigated using Boyden chambers. Results: In normal liver, both hepatocytes and HSCs were negative for all five SSTRs. Cirrhotic liver and HCC as well as cultured hepatoma cells and HSCs expressed all five SSTRs, both at the protein and mRNA levels, except for HuH7 cells which did not immunoreact with SSTR3. None of the agonists influenced proliferation or apoptosis. However, compared with untreated cells, L-797,591, an SSTR1 agonist, reduced migration of HepG2, HuH7, and HSCs significantly to 88 (7)% (p,0.05), 83 (11)% (p,0.05), and 67 (13)% (p,0.01), respectively. Conclusions: Cirrhotic liver and HCC express SSTRs. Although the somatostatin analogues used in this study did not affect proliferation and apoptosis, stimulation of SSTR1 may decrease invasiveness of HCC by reducing migration of hepatoma cells and/or HSCs. Clinical trials evaluating somatostatin analogues for the treatment of HCC should take these findings into account.
H epatocellular carcinoma (HCC) is one of the most feared complications of cirrhosis. It is a prevalent malignant tumour with an extremely poor prognosis. Radical curative surgery is performed in only a minority of patients with HCC. 1 2 Local treatment (for example, transcatheter arterial embolisation, radio frequency ablation, or percutaneous ethanol injection) is a therapeutic alternative in some cases. However, for large, diffuse, multifocal, or metastatic HCC, no standard therapy is available. 1 2 Because chemotherapy is associated with low response rates, other drugs with immunomodulatory and antiangiogenic properties are under investigation. 2 The ability of somatostatin to block hormone secretion led to the application of long acting somatostatin analogues for the treatment of endocrine tumours. However, as well as neuroendocrine tumours, some solid cancers also express somatostatin receptors (SSTR). 3 4 In vitro receptor autoradiography and radioligand binding studies have demonstrated that some HCCs also bear SSTRs. 5 6 Results of studies assessing the efficacy of somatostatin analogues on tumour progression and survival in humans with HCC are conflicting. In some studies, octreotide was found to improve significantly survival of patients with unresectable HCC 5 7 8 while these results were not confirmed by others. [9] [10] [11] Furthermore, a beneficial effect on tumour progression was reported 8 whereas in another study no significant effect was found. 7 The only two placebo controlled randomised trials did not show significant benefit of octreotide on patient survival and tumour progression. 9 12 On the other hand, quality of life and/or performance status were reported to be increased and treatment was generally well tolerated, without major side effects. 7 8 11 Somatostatin acts through five G protein coupled receptors (SSTR1-5). Pharmacological studies have shown that all subtypes bind to somatostatin 14 with high affinity whereas the long acting analogues octreotide, lanreotide, and vapreotide have high affinity for SSTR2 and SSTR5, intermediate affinity for SSTR3, and almost no affinity for SSTR1 and 4. 3 Whereas the majority of solid tumours bind octreotide with high affinity, some bind octreotide with low affinity. Furthermore, activation of different SSTRs results in different biological effects, emphasising the importance of identifying the exact SSTR subtype before initiating clinical trials with somatostatin analogues. 4 Therefore, the aim of the present study was to investigate expression of SSTR subtypes in human liver and to study the effects of SSTR subtype specific agonists on proliferation, apoptosis, and migration of hepatoma cell lines and hepatic stellate cells (HSCs).
MATERIALS AND METHODS

Tissues
Human liver tissue was obtained from surgical resection specimens at the time of partial hepatectomy or transplantation. No surgical procedures other than those planned were performed and no extra tissue was removed for the purpose of this study. Liver samples were obtained from patients with HCC and associated cirrhosis. Aetiology of cirrhosis was alcohol in three patients and hepatitis C in three patients. Samples from HCC as well as from surrounding cirrhotic liver were collected. In three patients, normal liver tissue was obtained at a site distant from resected solitary benign liver lesions. Specimens were processed in the pathology department (Hôpital Pellegrin, Bordeaux) and the laboratory for molecular liver cell biology (Vrije Universiteit Brussels). Samples were immediately frozen in either liquid nitrogen cooled isopentane for immunohistochemistry or directly in liquid nitrogen for reverse transcription-polymerase chain reaction (RT-PCR) experiments, and stored at 280˚C until used. HepG2 and HuH7 HCC cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. Human HSCs were isolated and cultured as described previously. 13 
Immunohistochemistry
For immunodetection of human SSTRs, subtype specific antibodies were used. These antibodies were developed and validated for immunohistochemistry in human tissue and were shown to be specific.
14 Double staining immunohistochemistry was performed as described previously, with minor modifications. 15 16 In short, 8-10 mm tissue sections were cut and fixed in methanol for 10 minutes at 220˚C. Non-specific binding was blocked by incubating sections with 2% albumin/phosphate buffered saline. The sections were incubated with a combination of primary antibodies to one of the five SSTRs and antibodies to platelet derived growth factor receptor b (PDGFR-b) or a smooth muscle actin (a-SMA). Sources, types, and dilutions of all antibodies are summarised in table 1. Peroxidase conjugated secondary antirabbit and alkaline phosphatase conjugated antimouse antibodies were added. Alkaline phosphatase was visualised with use of fast red TR/Naphtol AS-MX (Sigma-Aldrich, Bornem, Belgium). This reaction provided a red reaction product. Peroxidase was visualised by 3,39-diaminobenzidine/H 2 O 2 enhanced by Ni 2+ and Co 2+ ions, resulting in a black reaction product. Cells reacting with both primary antibodies stained brownish. After staining for nuclei with haematoxylin (Harris, Sigma, Bornem, Belgium), sections were mounted in DePeX (Dako, Merelbeke, Belgium) and were studied using a Zeiss Axioplan microsope (Zeiss, Jena, Germany). To further investigate the presence of different SSTRs on distinct cell types, human HSCs and two HCC cell lines, HepG2 and HuH7 cells, were exposed to SSTR antibodies for immunohistochemistry. In the presence of culture medium, cells were seeded on Falcon culture slides (Becton Dickinson Labware, Meylan, France) at a density of 5000 HSCs, or 10 000 HepG2 or HuH7 cells per chamber. Cells were exposed to SSTR antibodies and peroxidase conjugated secondary anti-rabbit antibodies, as described above.
PCR amplification
RNA was extracted using the RNeasy mini extraction kit (QIAgen, Westburg, the Netherlands) according to the manufacturer's manual. RNA extracted from human pancreas was used as a positive control.
14 A total of 187 ng of RNA was reverse transcribed using the RT-PCR core kit (Perkin-Elmer, New Jersey, USA), as described previously. 16 The reaction mixture (2.5 ml) was used for PCR amplification. cDNA was first denatured at 94˚C for 10 minutes followed by PCR for 35 cycles each consisting of a denaturation step (94˚C for one minute), an annealing step (69˚C for one minute), and a primer extension step (72˚C for one minute). Finally, an elongation step (72˚C for 10 minutes) was performed. In table 2, the primers used to amplify the five known SSTR subtypes are summarised. To check for contamination with chromosomal DNA, b-actin was amplified as described previously. 17 Specificity of all PCR products was confirmed by automatic sequencing using the ABI prism 310 (Perkin Elmer).
BrdU proliferation assay
To elucidate effects of somatostatin on tumour progression, SSTR subtype specific agonists were used: L-797,591 (SSTR1 agonist), L-779,976 (SSTR2 agonist), L-796,778 (SSTR3 agonist), L-803,087 (SSTR4 agonist), and L-817,818 (SSTR5 agonist) (Merck Research Laboratories, Rahway, New Jersey, USA). These substances are non-peptide somatostatin agonists with a very high subtype specificity, except for L-817,818 which has affinity not only for SSTR5 but also some for SSTR1. Although these substances have been used in animal cells, they were designed and developed as agonists for human SSTRs. The affinity of the agonists was tested in transfected CHO-K1 cells expressing each of the five human SSTRs. 18 In addition to their specificity, these agonists have a prolonged half life. Biological effects of the agonists has been tested in several cell lines and these effects were SSTR subtype specific. 19 Cell proliferation was measured by using the colorimetric 5-bromo-29 deoxyuridine (BrdU) cell proliferation ELISA (Boehringer, Mannheim, Germany), as described previously. 20 After trypsinisation, HepG2, HuH7, and HSCs were plated in 96 well dishes (Falcon, Becton Dickinson Labware, Meylan, France) at a density of 15610 3 , 15610 3 , and 6610 3 cells per well, respectively. All cells were suspended in DMEM supplemented with 2% fetal calf serum. After 24 hours, media were renewed and cells exposed for another 24 hours to different concentrations of SSTR agonists (10 212 to 10 28 mol/l) in the presence of 10 mmol BrdU. Platelet derived growth factor (PDGF-BB 10 ng/ml), a strong mitogen for HSCs, 21 was added to the medium of HSCs (R&D Systems Europe, Abingdon, UK). In each experiment, all conditions were tested 10 times, and every experiment was performed in triplicate. To allow comparison of proliferation between different groups, results were expressed as percentages and compared with controls normalised to 100%. Mean (SD) values were calculated for all groups.
In situ cell death detection Somatostatin induced apoptosis was studied by the TUNEL reaction according to the manufacturer's instructions (In Situ Cell Death Detection Kit; Roche diagnostics, Belgium). After trypsinisation, HepG2, HuH7, and HSCs were plated in 96 well dishes at a density of 2.5610 3 , 2.5610 3 , and 1610 3 cells per well, respectively. All cells were suspended in DMEM supplemented with 2% fetal calf serum. As apoptosis has been attributed to stimulation of SSTR2 and 3, different concentrations (10 212 to 10 26 mol/l) of L-779,976 and L-796,778, agonists of SSTR 2 and 3, respectively, were studied. After 24 and 72 hours of treatment, apoptotic cells were counted and expressed as a percentage of total cells. Experiments were performed in triplicate.
Cell invasion assay
The influence of the five SSTR agonists on migration of the hepatoma cell lines and HSCs was investigated, as described previously, 22 using Boyden invasion chambers with 8 mm pore size filters coated with Matrigel basement membrane matrix (Falcon, Becton Dickinson Labware, Bedford, Massachusetts, USA). PDGF-BB is a very strong chemoattractant for human HSCs 21 whereas hepatocyte growth factor (HGF) increases the invasiveness of HepG2 and HuH7 tumour cells. 22 To investigate the possibility that somatostatin inhibits PDGF-BB induced migration of HSCs or HGF induced migration of HepG2 and HuH7, cells were seeded in the upper well of Boyden chambers in the presence of PDGF-BB or HGF in the lower chamber. In these experiments, 2.5610 4 hepatoma cells or HSCs were seeded onto the filter. HGF 20 ng/ml (R&D Systems Europe, Abingdon, UK) was added to the lower chamber when hepatoma cells were seeded in the upper chamber, or PDGF-BB 10 ng/l was added when HSCs were present in the upper chamber. Subsequently, 10 29 mol/l of SSTR agonists were added to the cells in the upper chamber. After 12 and 48 hours for experiments with HSCs and hepatoma cells, respectively, cells in the upper chamber were wiped with a cotton swab, and the filters were fixed in methanol and stained with haematoxylin. Cells invading the lower surface of the filter were counted in 10 high power fields using a Zeiss Axioplan microscope. Results were expressed as a percentage, relative to controls normalised to 100%. Experiments were performed in triplicate, except for controls and experiments with L-797,591 (agonist of SSTR1) which were performed six times. 
Statistical analysis
One way analysis of variance (ANOVA) with Bonferroni's correction for multiple comparisons and the Mann-Whitney test were used when appropriate. Results are presented as means (SD). A p value of ,0.05 was considered statistically significant. Analysis was performed using Instat software (GraphPad software inc., San Diego, California, USA).
RESULTS
Immunohistochemistry
Using well validated specific antibodies against the five recognised SSTRs, we were able to localise the different SSTRs in sections of normal liver (fig 1), cirrhosis (fig 2) , and HCC (fig 3) . Expression of the various receptors varied between different specimens and cells (table 3) . In fig 1, normal liver is presented. Hepatocytes and sinusoidal cells did not stain for any of the five receptors. Cholangiocytes, on the other hand, consistently expressed SSTR subtypes 1, 3, and 4. Immunoreaction with SSTR subtypes 1 and 4 was more intense than with SSTR subtypes 2, 3, and 5 which were detected in, respectively, two, three, and one of the three analysed specimen. Furthermore, a weak immunoreaction of SSTR1 with endothelial cells of a small number of small arteries was found (not shown).
In cirrhotic liver, expression of SSTRs significantly changed compared with normal liver. Hepatocytes within cirrhotic nodules expressed SSTR1 (fig 2B, C) , and in 4/6 of the examined specimens, specimens also expressed SSTR2 (fig 2F,  G), SSTR3 (fig 2J, K), SSTR4 (fig 2N, O) , and SSTR5 (fig 2R,  S) . In most of the studied cases, we also found cells which double stained for all five SSTRs and a-SMA. These cells, clearly activated HSCs, were located at the interface of septa and cirrhotic nodules ( fig 2C, G, K, O) . In some specimens, we observed HSCs within hepatic nodules that stained for PDGFR-b and SSTR1 (fig 2D) or SSTR3 (fig 2L) .
In fig 3, immunohistochemistry for HCC is presented. Most of the tumours stained with SSTR subtypes 1 and 2 whereas 50% reacted with SSTR subtypes 3, 4, and 5 (table 3) . In some tumours, non-tumoral cells double stained for a-SMA and SSTR subtypes 1, 2, and 3 ( fig 3B, table 3) .
To verify the results of double staining immunohistochemistry, isolated cell lines were exposed to the different SSTR antibodies. Human HSCs were positive for all five SSTRs although immunoreaction with SSTR3 was less intense. Similarly, HepG2 expressed the five SSTR subtypes, again less clearly SSTR3. Finally, HuH7 reacted with all SSTRs, except for SSTR3 (data not shown).
Presence of SSTR mRNA in normal liver, cirrhosis, and HCC Messenger RNA of the five SSTRs was detected both in normal and pathological liver tissue (fig 4) . We identified a single band for all receptors, except SSTR4 for which three bands were found in some patients. Sequencing demonstrated that the middle band (635 nucleotides), which was most intense, corresponded to SSTR4. This was in agreement with the findings of Talme et al who used the same primers for SSTR4. 23 All investigated samples were definitely positive for SSTR subtypes 1 and 2. For these receptors, no important variations between different patients or between cirrhosis and tumour samples from the same patient were observed. Expression of mRNA of SSTR subtypes 3, 4, and 5 was almost undetectable in some patients whereas a significant band was observed in others. In two of six patients, surrounding cirrhotic tissue expressed SSTR4 and 5 mRNA more clearly than the tumour of these patients.
Presence of mRNA in cell lines
When examining expression of mRNA of the five SSTRs in different cell lines, we were able to demonstrate the presence of all receptors in HSCs, HepG2, and HuH7 cells ( fig 5) . In agreement with the results of liver tissue, a single band was demonstrated for SSTR subtypes 1, 2, 3, and 5 whereas multiple bands were found for SSTR4. Again, the middle band (635 nucleotides) was shown to correspond to SSTR4.
Effect of SSTR agonists on proliferation of HCC cell lines and HSCs
Proliferation of hepatoma cells and HSCs was stimulated with 2% fetal calf serum or PDGF-BB, respectively. As expected, PDGF-BB induced a marked increase in the proliferation of HSCs. 21 Proliferation of hepatocellular carcinoma cell lines HepG2 and HuH7, and HSCs did not change in the presence of different concentrations of various SSTR agonists compared with cells treated with PDGF-BB alone (data not shown). Human pancreas (P) was used as a positive control and water as a negative (Neg) control. Patients 1, 2, and 6 had hepatitis C related cirrhosis whereas patients 3, 4, and 5 had alcoholic cirrhosis. PCR reactions were performed on cDNA derived from 0.1875 mg PolyA + RNA for 35 cycles using SSTR subtype specific primers. Primers amplified only fragments corresponding to SSTR subtypes 1-5. b-Actin primers were used as a control to check for genomic DNA contamination. This reverse transcription-polymerase chain reaction is not quantitative and thus only statements on the presence, but not on the quantity, of mRNA can be made. Samples in lanes 1 and 2 were obtained from different gels. 
Effects of SSTR2 and 3 on apoptosis of hepatoma cells and HSCs
In preliminary experiments, no apoptotic effects of somatostatin agonists were observed. As somatostatin induced apoptosis has been attributed to activation of SSTR2 and 3, definitive experiments were performed with these agonists. No effects were observed in any of the three cell lines after 24 hours. Even when cells were treated for 72 hours with L-779,976 or L-796,778, no difference in apoptosis between treated and untreated cells was detected ( fig 6) .
Activation of SSTR1 reduces migration of hepatoma cells and HSCs
In the presence of chemotactic stimuli PDGF-BB or HGF in the lower part of the Boyden migration chamber, all three cell types migrated through the pores to the lower surface of the membrane ( fig 7A) . Among the five SSTR agonists tested, only addition of L-797,591 (SSTR1 agonist) significantly reduced migration ( fig 7B) . Compared with untreated control cells, migration of HepG2, HuH7, and HSCs significantly decreased to 88 (7)% (p,0.05), 83 (11)% (p,0.05), and 67 (13)% (p,0.01), respectively.
DISCUSSION
In this study, we have described expression of SSTR subtypes in normal human liver, in cirrhosis, and in HCC. Furthermore, we showed that migration of hepatoma cells and HSCs was reduced via activation of SSTR subtype 1.
However, the subtype specific somatostatin agonists used in this study had no effect on proliferation or apoptosis. Expression of SSTRs in human liver has not been studied in detail. In one study, SSTR2 was present in low amounts 24 although in another study using northern blot analysis, no relevant amounts of mRNA for any of the five SSTRs could be detected. 11 With the very sensitive RT-PCR technique, we were able to demonstrate the presence of all five SSTRs in normal human liver. By means of immunohistochemistry, we demonstrated that bile ducts, but not hepatocytes or sinusoids, immunoreacted with specific SSTR antibodies. Furthermore, SSTR1 was present in the endothelial cells of some small blood vessels, which is in agreement with findings in normal extrahepatic human blood vessels. 25 In a somatostatin 14/28 receptor binding study, levels of SSTRs were either absent, low, or very high in hepatitis and cirrhosis. 5 We also found considerable variation in SSTR expression in cirrhosis. Receptor subtypes 1 and 2 were prominent in most of the studied samples but SSTR 3, 4, and 5 were clearly present in some and absent in other specimens. As we did not use a quantitative PCR method, we cannot draw firm conclusions on the variation in mRNA expression. However, care was taken to start with equal amounts of mRNA, as proven by amplification of b-actin mRNA. Additionally, immunohistochemistry results confirmed the observations. Upregulation of SSTRs during liver disease is in agreement with our previous findings that rat HSCs expressed SSTRs in diseased but not in normal liver. 16 The ) * + , reason why SSTRs are upregulated during liver injury remains to be elucidated but it has been demonstrated in blood vessels and other tissues that injury, cytokines, growth factors, and somatostatin regulate SSTR gene expression. 3 26 Noteworthy is the fact that interface HSCs clearly express different SSTRs whereas lobular HSCs express mainly SSTR1. This may emphasise a possible role for a SSTR1 mediated decrease in portal hypertension via relaxation of HSCs. 16 However, we must emphasise that the cirrhotic tissues examined in our study were from patients with HCC. Further studies need to be performed in cirrhotic tissue of patients without HCC to rule out a possible effect of HCC on expression of SSTRs.
The presence of SSTRs has been described in HCC. 5 6 As measured by autoradiography, 41% of HCC were SSTR positive, predominantly subtype 2. previous studies, SSTR2 was expressed in two thirds of our studied samples. Again, both at the mRNA and protein levels, SSTR1 and 2 were most apparent, with intermediate expression of SSTR3 and low expression of SSTR4 and 5. In some samples we found myofibroblasts or HSCs that double stained for SSTRs and a-SMA. With RT-PCR and immunohistochemistry on isolated and cultured HepG2, HuH7, and HSCs, we were able to confirm our findings of SSTR expression in liver tissue.
It is clear from our own and other studies that there is considerable variation in expression of SSTRs in human HCC. The main question is, does activation of these receptors have antitumoral effects and, if so, through which receptor(s). It has been shown previously that antitumoral effects of somatostatin in other tumours are mediated directly by receptors present on the tumour cells resulting in growth arrest, apoptosis, or inhibition of migration and indirectly via inhibition of release of growth factors or cytokines, modulation of immune cells, and inhibition of neoangiogenesis. 4 27 28 The exact mechanism by which somatostatin could have an effect on progression of HCC remains to be elucidated. Previously, it has been shown in human hepatoma cell lines that somatostatin reduced proliferation of hepatoma cells only in the presence of insulin 29 or insulin-like growth factor, 11 which may be the reason why we did not observe any antiproliferative effect in our model. Using the same experimental set up in a study on hepatic fibrosis, equally we could not demonstrate any effect of somatostatin 14 on proliferation of HSCs (unpublished observations). The mechanism by which somatostatin reduces cell proliferation in hepatoma cells remains unresolved but it has been shown that octreotide induced insulin-like growth factor binding protein expression in human hepatoma cells, 30 which decreases bioactivity of insulin-like growth factor, a well recognised mitogen for hepatoma cells. 31 Apoptotic effects of somatostatin, attributed to SSTR2 and 3, 32 33 have been described with octreotide, 34 lanreotide, 11 and a tumour selective somatostatin analogue TT-232. 35 Using the TUNEL reaction, we were unable to show any significant SSTR2 or 3 induced apoptosis in any of the cell lines studied. As the TUNEL reaction preferentially labels DNA strand breaks generated during apoptosis, it allows discrimination of apoptosis from necrosis and from primary DNA breaks caused by cytotoxic drugs. This different experimental set up may explain the divergent results.
Migration, a key feature of malignant cells, was reduced via activation of SSTR subtype 1 in our study. Somatostatin may prevent cell migration and invasion in several ways. Firstly, it was demonstrated that somatostatin inhibited activation of Rho, the assembly of focal adhesions and actin stress fibres, and cell migration in response to both integrin and G protein coupled receptor mediated signals. 36 These effects were mediated through SSTR subtype 1. The Rho signalling pathway plays a critical role in tumour invasion and metastasis 37 and has been shown to be essential for intrahepatic metastasis in human HCC. 38 Moreover, a specific Rho kinase inhibitor, Y-27632, prevented Rho mediated cell migration of hepatoma cells 39 as well as intrahepatic metastasis of HCC. 40 Secondly, HGF, a very potent chemotactic factor for hepatoma cells, binds and activates a transmembrane receptor belonging to the receptor tyrosine kinase family. 41 Phosphorylation of the receptor by HGF activates phosphatidylinositol (PI) 3-kinase, ultimately resulting in migration of hepatoma cells. 42 All five SSTRs stimulate protein tyrosine phosphatase which inhibits the Ras-PI 3-kinase-Rac pathway by dephosphorylation of tyrosine kinase receptor. 3 Finally, SSTR subtypes 1 and 2 are linked to Ca +2 and K + channels and influence [Ca +2 ] i and thus cell contractility and motility. 3 Although tumour cells are most important, other cell types present in and around tumours play a crucial role in tumour progression. Indeed, in addition to carcinoma cells, a stromal compartment, including extracellular matrix, blood vessels, and myofibroblasts, is present in HCC. The role of HSCs/ myofibroblasts in HCC is not completely elucidated but most observations suggest that they could facilitate tumour progression, probably by secretion of HGF. 22 43-45 We showed reduced migration of HSCs via SSTR1. It is thus conceivable that reduced migration of HSC results in decreased invasion of tumour cells.
From our in vitro observations it seems that somatostatin has no major inhibitory effect on tumour growth. It should be kept in mind however that in this study SSTR subtype specific agonists were used. It remains possible that activation of a combination of SSTRs is necessary to inhibit tumour growth or induce apoptosis. As stated above, addition of growth factors (for example, insulin) to the culture media could alter the results. Furthermore, in vivo effects might be different from in vitro observations. Indeed, in addition to direct effects on the tumour, indirect effects may be of importance. 27 Although somatostatin has antiangiogenic effects in some tumours, 46 and HCC are highly vascularised, antiangiogenic effects of somatostatin in HCC have not been investigated to date. As mentioned above, octreotide suppressed hepatic expression and serum levels of insulin-like growth factor I and induced insulin-like growth factor binding protein. 30 47 Finally, hyperinsulinaemia, which has been associated with accelerated growth of HCC, was decreased by octreotide, resulting in reduced growth rate of HCC. 48 Clinical experience with somatostatin analogues is considerable and treatment is usually well tolerated, without major side effects. These are important considerations for the palliative treatment of inoperable HCC. However, maximal effort should be made to identify the optimal agonist(s) for maximal response. Using specific somatostatin agonists, we were unable to demonstrate any significant effect on proliferation and apoptosis in different cell lines. This could explain the marginal effect on tumour regression in most clinical studies. However, we showed reduced migration of HSCs and hepatoma cells via SSTR1. From our data, it seems that agonists of SSTR1 could prevent intra-and extrahepatic metastasis of HCC. To date, no long acting SSTR1 agonists have been tested in patients with HCC. Because somatostatin and analogues may have different effects in vivo, in vivo animal experiments with specific somatostatin analogues are awaited to confirm the in vitro data before initiating new randomised clinical trials in patients with advanced HCC.
